This issue of GEN highlights “points of intervention.” The phrase usually refers to specific functions in a human institution that can be modified to improve the institution’s overall effectiveness. (For example, a business might revamp its production technology to boost profits.) But there are also points of intervention in biological systems, such as our aging bodies. In our cover story, we explore how epigenetic, bioelectromic, synaptic, and senolytic interventions could slow or even reverse aging. Other articles discuss points of intervention relevant to processes such as vaccine development and AI-driven drug design. (Incidentally, institutions that investigate such points of intervention are highlighted in this month’s A-List, which ranks the top 50 recipients of NIH funding.) And finally, bringing our “points” discussion full circle, we have an article on Biopharma 5.0, which describes the interventions that are blurring the lines between the digital, biological, commercial, and social spheres.